The investment will extend Huma’s modular platform to power digital “home hospitals” nationwide, enabling the pharmaceutical and research industry to conduct the largest distributed clinical trials to date.
Hitachi, Samsung and Sony have invested in the latest Series C funding round in British health tech company Huma Therapeutics, raising about $ 130 million, the company said Wednesday.
A leap by Bayer and Hitachi Ventures led the Series C funding round, with Samsung Next, IGV’s Sony Innovation Fund, Uniliber Ventures, HAT’s HAT Technology and Innovation Fund, individual Nikesh Arora (former President, SoftBank) and Michael Diekmann (Chairman, Allianz).
In a statement, the investment will expand Huma’s modular platform to power digital “home hospitals” to enable the pharmaceutical and research industries to conduct the largest distributed clinical trials to date. He said he would support him.
According to the company, as part of its Series C funding, it will be able to raise another $ 70 million at a later date, bringing the total funding to over $ 200 million.
“We are already showing how’home hospitals’ can transform healthcare, and how distributed clinical trials can proceed in ways that were unimaginable even a year ago. Now we want to accelerate the pace of change and continue to innovate for better care and research around the world. “Huma’s founder and CEO, Dan Vahdat, said.
The new investment will be used to expand Huma’s digital platform in the United States, Asia and the Middle East.
The digital “home hospital” was created in collaboration with clinicians to show that clinical capacity has almost doubled, readmissions have been reduced by more than a third, and patient adherence levels have exceeded 90%. It has been.
“This service supports the government’s pandemic response on a non-profit basis and is currently used by a variety of patients,” the company said.
Huma works with major life sciences companies such as AstraZeneca, Bayer and Janssen, as well as academic institutions such as Stanford Medicine, Johns Hopkins Bloomberg School of Public Health and the University of Cambridge.
Jonathan Machado, Senior Investment Director at Samsung Next, said:
Hitachi, Samsung and Sony invest $ 130 million in human therapies
Source link Hitachi, Samsung and Sony invest $ 130 million in human therapies